

Antoine Turzi & REGEN LAB team
BIOBRIDGE FOUNDATION

«Wound Gel» PRP/Thrombin & Tissue Engineering in Wound Management



Officina Editoriale Oltremo

«Wound Gel» PRP/Thrombin & Tissue Engineering in Wound Management

Antoine Turzi & REGEN LAB Team, Biobridge Foundation

The Publisher is available to address any communication challenges with entitled individuals and rectify any omissions or inaccuracies in source citations.

This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or used in any other media. The Publishing House reserves the right to take legal action for its protection against those who arbitrarily do not comply with this rule. Furthermore, the editor, authors, and publisher are not responsible for errors, omissions, or any consequences arising from applying the information in this book. They do not guarantee, expressly or implicitly, the completeness, accuracy, or correctness of the content of the publication. The application of this information remains the professional responsibility of the doctor.

The Editor

Editorial project:

Davide Di Maggio
davide@oefirenze.com

Layout and Web page:

Roberta Dolce

Customer management:

Andrea Ortolani
andrea@oefirenze.com

Production secretary:

Carlotta Cirri
carlotta@oefirenze.com

ISBN: 9791280318473

Officina Editoriale Oltrarno S.r.l. - Firenze

www.oefirenze.com
info@oefirenze.com
digital.oefirenze.com



«Wound Gel» PRP/Thrombin & Tissue Engineering in Wound Management

This internationally available publication consists of information regarding the current state of Platelet Rich Plasma (PRP) obtained through the practice of medicine and clinical research. Throughout this publication, there are references to certain medical devices which have been cleared by the US Food and Drug Administration (FDA), but which are also available world-wide. For the use of those devices in the USA, Regen Lab only promotes and supports their indicated and intended use in order to comply with US FDA Guidelines. If you have any questions or inquiries, please contact the legal department at compliance@regenlab.com.

BioBridge Foundation
www.biobridge-event.com/knowledge

Regen Lab SA
www.regenlab.com

CONTRIBUTORS

Antoine Turzi

Founder & President of RegenLab group,
Regen Lab SA, Le Mont sur Lausanne, Switzerland

Marco Romanelli, MD PhD

Department of Dermatology, University of Pisa, Pisa, Italy

Flavia Manzo Margiotta, MD

Department of Dermatology, University of Pisa, Pisa, Italy

Alessandra Michelucci, MD

Department of Dermatology, University of Pisa, Pisa, Italy

Sylvaine Clavel, MD

Department of Endocrinology, SOS Group–Hotel Dieu, Le Creusot, France

Chantal Denizot

Pre-Re-Diab Network, Le Creusot, France

Bruno Boëzennec, MD

RegenLab SA, Le Mont-sur-Lausanne, Switzerland

Nizar Albache, MD

Department of Endocrinology, SOS Group–Hotel Dieu, Le Creusot, France

Axel Hempfing, MD

Orthopaedic Specialist, Head of the Spinal Paralysis Center
Werner Wicker Clinic – Center for Spinal Cord Injury, Bad Wildungen/Reinhardshausen, Germany

Jens Schmücker, MD

Specialist in Traumatology, Orthopaedics and Reconstructive Surgery,

Werner Wicker Clinic – Center for Spinal Cord Injury, Bad Wildungen/Reinhardshausen, Germany

Dmytro Bychkov, PhD

Scientific Clinical Liaison at RegenLab USA
Jersey City, New Jersey, United States

Beuste Stefanelli, MD

Plastic Surgery and Hand Surgery Unit, RSV Sierre Hospital, Switzerland

Pr. Karim el Khatib, MD, PhD

Professor, Head of Department at Mohammed V University

Dmytro Golovatiuk, MD, PhD

Assistant professor of the Department of Pediatric Surgery at the Bogomolets National Medical University

Brice Tchackerian, MD

Clinical Lecturer at the University Hospitals of Paris and Assistant Physician at Henri-Mondor University Hospital, APHP, in the Department of Plastic, Reconstructive, Aesthetic, and Maxillofacial Surgery, Paris, France

Sandra Fraud-Cremer, MD

Department for Vascular and Endovascular Surgery, University Hospital of Schleswig-Holstein, Campus Kiel

Irma Kasic

Wound expert, Department for Vascular and Endovascular Surgery, University Hospital of Schleswig-Holstein, Campus Kiel

Rene Rusch, PhD

Department for Vascular and Endovascular Surgery, University Hospital of Schleswig-Holstein, Campus Kiel

Dr. Solange Vischer

Scientific advisor Regen Lab SA, Le Mont sur Lausanne, Switzerland

Sarah Berndt, PhD

Obstetrician-gynecologist, The Clinical Institute of Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva, Switzerland;
Faculty of Medicine, Geneva University, Geneva, Switzerland;
Regen Lab SA, Le Mont-sur-Lausanne, Switzerland

Ali Modarressi, MD

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva, Switzerland;
Faculty of Medicine, Geneva University, Geneva, Switzerland

Marc Divaris, MD

Service de Chirurgie Maxillo- Faciale et Plastique Hôpital
Salpêtrière, Université Paris 6, France

Marie-Christine Branchet, PhD

GREDECO (Group of Research and Evaluation in
Dermatology and Cosmetology),
Paris, France

Sylvie Boisnic, MD

GREDECO (Group of Research and Evaluation in
Dermatology and Cosmetology),
Paris, France

Marine Delcros, MD

Regen Lab SA, 1052 Le Mont-sur-Lausanne, Switzerland

Hugues Mondésert, PhD

Regen Lab SA, Jersey City, New Jersey, USA

Dr. Christian Buckley, PhD

Regen Lab SA, Jersey City, New Jersey, USA

TABLE OF CONTENTS

Preface	9
<i>Antoine Turzi</i>	
1. State of the Art with Pr Romanelli: Wound Care from Yesterday to Today	11
<i>Marco Romanelli, MD PhD - Flavia Manzo Margiotta, MD - Alessandra Michelucci, MD</i>	
2a. A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of an Autologous Standardized Leukocyte-Poor Platelet Gel with Standard Care for the Treatment of Chronic Neuropathic Diabetic Foot Ulcers	25
<i>Sylvaine Clavel, MD- Chantal Denizot - Bruno Božennec, MD - Antoine Turzi - Nizar Albache, MD</i>	
2b. Clinical Results and Cost-Effectiveness of RegenWound Gel	35
2c. Management and Evaluation of Medical Devices: the Case of Regenkit in DFUs Treatment	47
2d. Cost-Effectiveness and Clinical Efficacy of Platelet-Rich Plasma in Diabetic Foot Ulcers and Knee Osteoarthritis - Evaluation by Our Moroccan Experts	55
3a.I. Autologous Keratinocyte Suspension in Platelet Concentrate Enhances Wound Healing of Skin Graft Donor Sites: a Clinical Innovation Patented by Antoine Turzi in 2004 and 2006	58
3a.II. PRP-Thrombin Gel Combined with Split-Thickness Skin Graft for Post-Infectious Skin Defects	61
3b.I Clinical Case Summaries: Autologous PRP for Chronic Leg Ulcers of Mixed Etiologies	64
3b.II. Successful Use of RegenPRP® in the Treatment of a Sacral Pressure Ulcer in a Patient with Spinal Cord Injury	68
<i>Axel Hempfing , MD - Jens Schmücker, MD</i>	
3c.I. Clinical Case Summary: Autologous PRP for Diabetic Foot Ulcer Healing	70
3c.II. Other Clinical Cases in the United States of America: Application of Woundgel® on Diabetic Wounds	73
<i>Dmytro Bychkov, PhD</i>	
3d. Platelet-Rich Plasma (PRP) Use in Infection Prevention	75
3e. Clinical Case Summaries: PRP in Management of Severe Radio-Epidermitis	80
3f. Treatment of Deep Burns with Autologous PRP + ATS Gel	83
<i>Beuste Stefanelli, MD</i>	
3g. Platelet Rich Plasma (PRP) Gel Technology in the Treatment of Traumatic Chronic Wounds: Clinical Case Synthesis	84
<i>Pr. Karim el Khatib, MD, PhD - Dmytro Golovatiuk, MD, PhD</i>	
3h. Angiogenesis and Clinical Cases	92
3i. Summary in Vitro Studies on Regenkit PRP Applications	94

3j. PRP & Rhinoplasty - Clinical Cases	96
<i>Brice Tchackerian, MD</i>	
3k.I. Application of Combination of Autologous Platelet-Rich Plasma (PRP), Autologous Thrombin Serum (ATS), and Calcium Gluconate (CaGlu). Various German Cases	99
3k.II. Platelet-Rich-Plasma (PRP) in Vascular Surgery – Wound Care	104
<i>Sandra Fraund-Cremer, MD - Irma Kasic - Rene Rusch, PhD</i>	
3l. Summary of Recent Meta-Analysis on the Use of Autologous Platelet Rich Plasma for Chronic Wounds	108
<i>Dr. Solange Vischer</i>	
4. Platelet-Rich Plasma in Chronic Wound Healing: a Dual-Action Approach Enhancing Angiogenesis and Fibroblast Regeneration	113
<i>Sarah Berndt, PhD - Ali Modarressi, MD - Antoine Turzi</i>	
5. Demonstration of Modifications in Capillaries and Fibrous Tracts at the Hypodermis Level After Injection of PPR Alone or Associated with Thrombin on a Human Skin Model	119
<i>Marc Divaris, MD - Marie-Christine Branchet, PhD - Sylvie Boisnic, MD</i>	
6. Summary of Recent Meta-Analysis on the Use Of Autologous Platelet Rich Plasma for Chronic Wounds	123
<i>Dr. Solange Vischer</i>	
7. An Overview of RegenLab Technologies	128
<i>Dr. Solange Vischer</i>	
8a. Standardized and Reproducible PRP Preparation Using RegenLab's Thixotropic Gel Technology: Clinical and Technical Evidence (2019–2025)	140
8b. Comprehensive Evaluation of the RegenBMC® System for PRP Preparation and Its Application in Bone Grafting	143
8c. Enhancing Adhesion Between 3D Scaffolds and Bone Substitutes Using a PRP/ATS-Based Bioadhesive	145
9. Bioresorbable Dressing	148
<i>Marine Delcros, MD - Hugues Mondésert, PhD - Christian Buckley, PhD</i>	
10. Overview of RegenLab's Patents in Woundcare	154
Conclusion	167
<i>Antoine Turzi</i>	



A-CP

Volume: 10 ml

Medium: Corate & Gel

2023-05-25

ID:

REGEN LAB SA
14052 Mont-sur-Lausanne
Switzerland

Preface

RegenLab was founded to develop autologous blood-derived technologies such as PRP (Platelet-Rich Plasma) and ATS (Autologous Thrombin Serum), and subsequently a new generation of biodegradable & bioresorbable tissue-engineered bandages and implants. It has become our mission to create innovative medical solutions based on the body's natural resources, to benefit both patients and public health.

Among these challenges, the treatment of chronic wounds remains one of the most significant medical and societal issues. Chronic wounds represent a substantial burden for healthcare systems: they are slow to heal, often painful, susceptible to infection and complications, and have a profound impact on patients' quality of life. By harnessing the body's intrinsic regenerative potential, our proprietary REGENPRP technology helps accelerate wound closure and reduce complications, while integrating seamlessly into existing care protocols. These concrete clinical outcomes continue to strengthen our commitment to this pathway.

This progress has only been possible through close collaboration with healthcare professionals. We are privileged to work with dedicated physicians who support and challenge us, sharing our vision of accessible regenerative medicine — evidence-based and grounded in real-world clinical practice. These field-driven exchanges, always rich and demanding, are at the heart of our scientific approach and guide our development strategies.

Today, the wound care landscape still leaves much to be desired.

While many business leaders continue to profit from outdated approaches such as Negative Pressure Therapy (NPT), these technologies have shown limited added value compared to biologics. Once debridement is complete, wounds often proceed to healing simply with advanced solutions such as our Wound Gel.

In the United States, the rapid expansion of skin substitutes based on umbilical extracts has faded, often surrounded by controversy, due to prohibitively expensive dressings that lack demonstrated efficacy. We remain hopeful that the implementation of CMS's Local Coverage Determination (LCD) will soon restore greater clinical and economic rationality to this field.

Encouragingly, recent decisions by both the US FDA and CMS mark a significant turning point, as they increasingly recognize blood-derived products for chronic wound indications. The introduction of the CMS National Coverage Determination (NCD) for FDA-approved technologies represents a critical step forward.

A new paradigm is emerging: one where clinical efficacy is clearly demonstrated—not only for wound closure, but also for the prevention of amputations, sometimes with just a single application, as evidenced in Dr. Clavel's study. The associated health economic benefits have been robustly demonstrated, notably in the work of Professor Russo, economist at Ca' Foscari University.

We invite you to explore the scientific and clinical evidence presented in this book. Do not hesitate to share your feedback and, if possible, to conduct your own evaluations using our technologies. Your contribution will help to further advance the field.

Our ambition is clear: to continue innovating while remaining deeply connected to clinical practice; to provide healthcare professionals with tools that are reliable, effective, and tailored to their needs; and, above all, to keep the patient at the center of everything we do.

In conclusion, the recognition of these new approaches — now reimbursed by CMS and approved by the FDA — offers great promise for patients and healthcare systems alike. We hope that this book will provide you with valuable insights, and we warmly invite you to engage with us, share your experiences, and contribute to the ongoing discussion. The future of wound care is taking shape and the path forward is open.

*Antoine Turzi,
President – RegenLab SA*

